Description for medicine or protocol of treatment in detail:
|
Medicinal ingredients: black-bone chicken (detrimental intestines), salvia miltiorrhiza, rehmannia glutinosa, Cyperus rotundus (vinegar), ginseng, white peony root, oysters (calcined), antler cream, silver chaihu, licorice, astragalus, turtle shell (made), papaya Protease, paraffin wax.
Treatment plan: oral. Take 2 to 3 capsules at a time, 3 times a day.
|
Inclusion criteria
|
Subjects who meet all the following selection criteria can be included in this study:
1) Women aged 18-40 (including 18 years old) who are diagnosed with premature ovarian failure, or women aged 40-55 (including 40 and 55 years old) who are diagnosed with menopausal syndrome;
2) Patients with premature ovarian failure: In two tests with an interval of more than 1 month, serum FSH> 40 IU/L, E2 <185pmol/L, and at least 6 months of amenorrhea; patients with menopausal syndrome: menstrual disorders or Menopause for more than 3 months, FSH>10 IU/L, and modified Kupperman score ≥16 points;
3) Have a detailed understanding of the nature, significance, possible benefits and possible inconvenience and potential dangers of the trial before the trial, and voluntarily participate in this clinical trial, can communicate well with the investigator, comply with the requirements of the entire study, and sign A written informed consent form was obtained.
|
Exclusion criteria:
|
Subjects who meet one or more of the following criteria will be excluded:
1) Participated in other drug clinical trials within 3 months;
2) (Inquiry) Diseases with abnormal clinical manifestations that need to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism and bone systems People with diseases, and the investigator believes that these diseases may affect the results or safety of subjects participating in the study;
3) (Inquiry) Those with thrombotic disease, severe liver and kidney dysfunction;
4) (Inquiry) Patients with estrogen-dependent malignant tumors such as breast cancer, ovarian cancer, and endometrial cancer;
5) (Inquiry) Patients with bilateral ovarian resection and gynecological organic disease (hysteromyoma tumors larger than 2cm) and severe breast hyperplasia;
6) The results of vaginal B-ultrasound and breast B-ultrasonography are judged by clinicians as abnormal and clinically significant;
7) (Inquiry) Those who have received hormone replacement therapy (HRT) medications within 3 months, or health products with estrogen effects, Chinese patent medicines, Chinese medicines (royal jelly, soybean isoflavones, motherwort granules, Wuji Baifeng pills, Ziheche, Xiaoyao Pills, Kunbao Pills, Eucommia, Pueraria lobata, Angelica, Motherwort, Houttuynia cordata, Lysimachia, Scutellaria, etc.) healer;
8) (Inquiry) Those who have a history of specific allergies (asthma, urticaria, eczema, etc.), or those who are allergic to any medicine, food or pollen, or who are known to be allergic to Jinhong? Wuji Baifeng Soft Capsules;
9) (Inquiry) Subjects who have a childbirth plan or egg donation plan during the trial period to 3 months after the last dose, and are unwilling or fail to take effective contraceptive measures;
10) General physical examination, laboratory examination (blood routine, urine routine, liver and kidney function, pregnancy test, etc.) within 7 days before the test, ECG within 14 days before the test, and chest X-ray results within 6 months before the test are judged to be abnormal by the clinician Have clinical significance;
11) (Inquiry) Those who cannot eat or have difficulty swallowing;
12) (Inquiry) Those who have a history of asthma, epileptic seizures, or mental illness;
13) The investigator believes that the compliance is poor, or subjects who have any factors that are not suitable for participating in this trial.
|